Microbio Co. Ltd

Detailed Description

Microbio Co., Ltd. develops and sells various therapeutics in Taiwan. It offers nutritional supplements, skin care products, and organic agricultural products. The company also provides MS-20 for ameliorating fatigue and appetite loss associated with cancer chemotherapy; and Herbiron, which reveals symptoms of iron deficiency anemia and menstrual discomfort. Its pre-clinical stage products include SNS01, SNA02, and SNA-03 to treat various types of cancers, as well as SNA-07 for cancer immune therapy; and SNP-630 to treat non-alcoholic steatohepatitis. The company's Phase I clinical trial products consist of OB-318, an anti-cancer drug; MB-110 for the treatment of hepatitis C; SNP-810, an acetaminophen; FB317 to treat moderate-to-severe allergic asthma and chronic idiopathic urticaria; and FB704A for the treatment of rheumatoid arthritis, cancer, and cytokine storms. In addition, it offers FB825, which is in Phase II clinical trial for the treatment of atopic dermatitis, allergic asthma, hyper IgE syndrome, and food allergy. Additionally, the company's Phase III clinical trial products comprise ON101 to treat diabetic foot ulcer; and MB-6 that acts as an adjuvant for metastatic colorectal cancer. Further, the company's discovery stage pipeline includes FB121 for AIDS; SNA01 to treat PD-1 related cancer; SNA02 for cancer immune therapy; and SNS01 for recurrent metastatic non-small cell lung cancer. Microbio Co., Ltd. was founded in 2000 and is based in Taipei, Taiwan.